InnovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Year: 2024
Type: conference-paper
Authors: Kosei Hasegawa, Brian M. Slomovitz, Antonio González Martín, Keiichi Fujiwara, Elsa Kalbacher, Andrea Bagaméri, Sharad Ghamande, Jung-Yun Lee, Susana Banerjee, Fernando Maluf, Domenica Lorusso, Kan Yonemori, Els Van Nieuwenhuysen, Luis Manso Sánchez, Linn Woelber, Anneke Westermann, Allan Covens, Elizabeth Whalley, Melinda Siew Leng Teng, Ibrahima Soumaoro, Ignace Vergote
Institutions: The University of Texas MD Anderson Cancer Center, Saitama International Medical Center, Saitama Medical University, University of Oklahoma Medical Center, Mount Sinai Medical Center, Clinica Universidad de Navarra, Centre Hospitalier Universitaire de Besançon, Augusta University, Yonsei University, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Beneficência Portuguesa de São Paulo, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, National Cancer Center Hospital, Universitair Ziekenhuis Leuven, KU Leuven, Hospital Universitario 12 De Octubre, University Medical Center Hamburg-Eppendorf, Amsterdam University Medical Centers, Sunnybrook Hospital, Sunnybrook Research Institute, Seagen (United States), Genmab (United States)
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4398213690